z-logo
Premium
The Salmonella pathogenicity island‐2 subverts human NLRP3 and NLRC4 inflammasome responses
Author(s) -
Bierschenk Damien,
Monteleone Mercedes,
Moghaddas Fiona,
Baker Paul J.,
Masters Seth L.,
Boucher Dave,
Schroder Kate
Publication year - 2019
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.ma0318-112rr
Subject(s) - inflammasome , nlrc4 , pyroptosis , salmonella , biology , pyrin domain , microbiology and biotechnology , innate immune system , immune system , pathogenicity island , macrophage , caspase 1 , inflammation , immunology , bacteria , biochemistry , genetics , in vitro
Inflammasomes are signaling hubs that activate inflammatory caspases to drive cytokine maturation and cell lysis. Inflammasome activation by Salmonella Typhimurium infection or Salmonella ‐derived molecules is extensively studied in murine myeloid cells. Salmonella ‐induced inflammasome signaling in human innate immune cells, is however, poorly characterized. Here, we show that Salmonella mutation to inactivate the Salmonella pathogenicity island‐2 type III secretion system (SPI2 T3SS) potentiates S . Typhimurium‐induced inflammasome responses from primary human macrophages, resulting in strong IL‐1β production and macrophage death. Inactivation of the SPI1 T3SS diminished human macrophage responses to WT and ΔSPI2 Salmonella . Salmonella ΔSPI2 elicited a mixed inflammasome response from human myeloid cells, in which NLR family CARD‐domain containing protein 4 (NLRC4) and NLR family PYRIN‐domain containing protein 3 (NLRP3) perform somewhat redundant functions in generating IL‐1β and inducing pyroptosis. Our data suggest that Salmonella employs the SPI2 T3SS to subvert SPI1‐induced NLRP3 and NLRC4 inflammasome responses in human primary macrophages, in a species‐specific immune evasion mechanism.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here